The use of ischemia modified albumin as a predictive and prognostic biomarker in patients with non-acetaminophen- induced acute liver failure

Basit Öğe Kaydı
dc.contributor.authorAktas, Aydin
dc.contributor.authorGunes, Orgun
dc.contributor.authorBudak, Fatma Olmez
dc.contributor.authorDiller, Nilufer
dc.contributor.authorTuncer, Adem
dc.contributor.authorAkbulut, Sami
dc.contributor.authorTaskapan, Mehmet Cagatay
dc.date.accessioned2024-08-04T19:42:46Z
dc.date.available2024-08-04T19:42:46Z
dc.date.issued2022
dc.departmentİnönü Üniversitesien_US
dc.description.abstractAim: This study aimed to investigate to usability of ischemia modified albumin (IMA) and IMA/albumin ratio (IMAR) values in the follow-up of ALF patients. King College criteria (KCC) and Model for End-Stage Liver Disease (MELD) score are the most commonly used criteria in the follow-up of patients with acute liver failure (ALF). However, these criteria cannot always predict prognosis and the need for liver transplantation (LT). Materials and Methods: IMA and IMAR values of 23 ALF patients and 43 healthy volunteers were measured. Then IMA and IMAR values were compared with KCC and MELD score to predict LT requirement and prognosis in ALF patients. Results: IMA and IMAR values were significantly higher in ALF patients compared healthy volunteers (p=0.001, p=0.001; respectively). IMA and IMAR values predicted LT requirement in ALF patients such as KCC and MELD (?30) score (p=0.006, p=0.04, p=0.001, p=0.03; respectively). IMA values were found to better than KCC in predicting mortality (p=0.008, p=0.02; respectively). MELD (?30) score failed to predict mortality (p=0.44). Conclusion: IMA and IMAR values can be used as diagnostic biomarkers in ALF pa- tients. IMA is a better prognostic biomarker in the follow-up of ALF patients.en_US
dc.identifier.endpage852en_US
dc.identifier.issn2636-7688
dc.identifier.issue8en_US
dc.identifier.startpage846en_US
dc.identifier.trdizinid1126814en_US
dc.identifier.urihttps://search.trdizin.gov.tr/yayin/detay/1126814
dc.identifier.urihttps://hdl.handle.net/11616/88666
dc.identifier.volume29en_US
dc.indekslendigikaynakTR-Dizinen_US
dc.language.isoenen_US
dc.relation.ispartofAnnals of Medical Researchen_US
dc.relation.publicationcategoryMakale - Ulusal Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.titleThe use of ischemia modified albumin as a predictive and prognostic biomarker in patients with non-acetaminophen- induced acute liver failureen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

TR-Dizin İndeksli Yayınlar Koleksiyonu